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A B S T R A C T
We compared the survival of patients following the first AIDS event in Croatia from the period 1986–1996 to the pe-
riod 1997–2000. A total of 72 (81.8%) out of 88 patients from 1986–1996 and 18 (32.1%) out of 56 from 1997–2000 died.
Survival following the first AIDS-defining illness markedly improved in the period 1997–2000 compared to the period
1986–1996 (adjusted Hazard Ratio (HR) for patients surviving more than 6 months: 0.11, 95% confidence interval (95%
CI)=0.04–0.29). A CD4+ cell count of <100  106/L was an independent risk factor for patients surviving up to 2 years
(adjusted HR=1.96, 95% CI=1.1–3.43, p=0.02). Patients with tuberculosis or fungal infections had a longer survival
when compared to other diagnosis (adjusted HR=0.53, 95% CI=0.32–0.90, p=0.01). However, despite dramatic survival
benefit of combination antiretroviral therapy, mortality at six months following the first AIDS event was similar in the
two study periods and the one-year probability of death was still substantial (27.2%) in the period 1997–2000.
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Introduction
Croatia is a South-Eastern European upper middle
income country with a low level HIV-epidemic1. Up to
December 2000, 174 cases of AIDS had been reported,
most (46%) were diagnosed among men who have sex
with men. Highly active antiretroviral treatment (HAART)
has been provided universally and free of charge in
Croatia through the national health care system since
April 1998. Studies in developed countries have demon-
strated striking benefits from HAART in terms of sur-
vival2–9. However, there are fewer reports from develop-
ing countries and none from South-Eastern European
countries10.
Croatia has a centralized system of care for HIV/
AIDS and all patients are treated at University Hospital
of Infectious Diseases (UHID) in Zagreb. The aim of this
study was to compare the survival of Croatian patients
after AIDS diagnosis in the pre-HAART era (1986–1996)
to the early HAART era (1997–2000).
Subjects and Methods
In this study, data were collected retrospectively up to
1998 and prospectively thereafter. Included were pa-
tients over 15 years of age in whom the first AIDS-defin-
ing event was diagnosed at UHID. The 1993 European
AIDS case definition (CDC category C) was used11 as the
inclusion criterion. Variables included as determinants of
mortality were: age at AIDS diagnosis, sex, transmission
category, initial AIDS defining illness, CD4+ cell count,
Pneumocystis jiroveci pneumonia (PCP) prophylaxis, an-
tiretroviral therapy, and era of diagnosis (pre- HAART
1986–1996; early HAART 1997–2000). Each patient was
considered as a censored observation at the time of last
contact if lost to follow-up or known to be alive on De-
cember 31, 2002. To ensure the accuracy of the date of
death, we compared our records with official mortality
statistics obtained from the Croatian Public Health In-
stitute.
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Survival times were calculated using the Kaplan-
Meier method. Cox's proportional hazards model was
used to examine factors associated with survival on bi-
variate and multivariate analysis. We included in the
multivariate model predictors of survival with p<0.20 on
bivariate comparison. Log-log plots and Schoenfeld resid-
uals were used to check the validity of the proportional
hazards assumption. Because the categories of CD4+ cell
count and era of diagnosis violated this assumption dif-
ferent survival periods were modeled for these variables
according to the log-minus-log survival plot. We assumed
that the hazard changed at 6 months for the era of diag-
nosis and at 24 months for the CD4+ cell count. PCP pro-
phylaxis was also time dependently modeled as was the
type of antiretroviral treatment (monotherapy, double
therapy and HAART). Both were modeled in an intention
to treat fashion by fitting a 0/1 variable which coded 1
when the patient had started the drug. No adjustments
were made for stopping or changing antiretroviral treat-
ment or PCP prophylaxis. Because the variables era of
diagnosis and type of antiretroviral treatment were cor-
related we constructed separate models for each of them.
Statistical tests were conducted using SAS software ver-
sion 8.2 (SAS Institute, Inc., Cary, North Carolina, USA).
Results
The population included 144 (82.8%) out of 174 AIDS
patients registered in Croatian´s National HIV/AIDS
Registry in the period 1986–2000. Of these, 88 (61.1%)
were treated in the pre-HAART era and 56 in the early
HAART era. The main characteristics of the patients are
presented in Table 1. 17 (19.3%) patients from the period
1986–1996 and 48 (85.7%) from the period 1997– 2000
received HAART. The median time of initiation of
HAART following the first AIDS event was 134 days
(interquartile range: 66 to 359 days) for all patients and
for patients in the HAART era it was 100.5 days (in-
terquartile range: 54.5 to 210.5 days). Altogether, 90
(62.5%) patients died; 72 (81.8%) from the pre-HAART
era and 18 (32.1%) from the HAART era. The one-, three-
and five-year survival probabilities in the pre- HAART
era were 52.1%, 22.5% and 15.4% whereas in the HAART
era they were 72.8%, 68.4% and 61.9% respectively
(Kaplan-Meier method). Patients treated in the HAART
era had more frequently a lower CD4+ cell count (below
100  106/L CD4+ cells) compared to patients in the
pre-HAART era (72% versus 36.4%, p< 0.001) (Table 1).
Seven patients started antiretroviral monotherapy prior
to AIDS, 5 of whom where from the 1986–1996 period.
Only one patient started double antiretroviral therapy,
and none started HAART prior to AIDS. The median age
at AIDS diagnosis was 37.8 years (range: 15.9 to 65.5
years) and 39.7 years (range: 23.1 to 73.5 years) in the
pre-HAART and early HAART era respectively. The me-
dian survival for patients treated in the period
1986–1996 was 13.7 months, whereas it was not reached
for patients treated in the period 1997–2000 (Figure 1).
Predictors of longer survival using bivariate analysis
were: era, antiretroviral treatment, type of presenting
AIDS-defining illness, and PCP prophylaxis (Table 2).
The hazard of death up to 6 months after AIDS diagnosis
was similar in the two eras; however, afterwards it was
markedly reduced for patients treated in the early HAART
era, 1997–2000 (Table 2).
In multivariate analyses, survival was markedly in-
creased for patients who received HAART (Table 2). A
CD4+ cell count of <100  106/L was an independent risk
factor for death for patients surviving up to 2 years. Pa-
tients with tuberculosis/fungal infections had better sur-
vival when compared to other diagnoses, and PCP pro-
phylaxis did not reach significance in predicting survival
difference (Table 2). When the era was included in the
multivariate model, and the type of antiretroviral ther-
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Fig. 1. The Kaplan-Meier product-limit estimates of the probability of survival after AIDS diagnosis in periods 1986–1996
and 1997–2000. Ticks indicate censored observations.
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TABLE 1
CHARACTERISTICS OF THE ADULT CROATIAN AIDS PATIENTS DIAGNOSED IN THE PERIOD 1986–1996 AND 1997–2000
Patients characteristics
Time of diagnosis
Total
(N=144)
n (%)
p1986–1996
(N=88)
n (%)
1997–2000
(N=56)
n (%)
Age at diagnosis
15–39 47 (53.4) 26 (46.4) 73 (50.7) 0.495
40 41 (46.6) 30 (53.6) 71 (49.3)
Gender
Male 73 (82.9) 49 (87.5) 122 (84.7) 0.635
Female 15 (17.1) 7 (12.5) 22 (15.3)
Exposure category
Heterosexual 33 (37.7) 28 (50) 61 (42.4) 0.277a
MSM/bisexual 42 (47.7) 23 (41.1) 65 (45.1)
IVDU 8 (9.1) 4 (7.1) 12 (8.3)
Blood/blood products 5 (5.7) 0 (0.0) 5 (3.5)
Unknown 0 (0.0) 1 (1.8) 1 (0.7)
Presenting diagnosisb
Tuberculosis (pulmonary/extrapulmonary) 20 (22.7) 10 (17.9) 30 (20.8) 0.534c
Pneumocystis jiroveci pneumonia 17 (19.3) 8 (14.3) 25 (17.4)
Cryptococcal meningitis 8 (9.1) 8 (14.3) 16 (11.1)
Oesophageal candidiasis 11 (12.5) 11 (19.6) 22 (15.3)
HIV encephalopathy 10 (11.4) 4 (7.1) 14 (9.7)
Kaposi sarcoma 9 (10.2) 3 (5.4) 12 (8.3)
Other 24 (27.3) 20 (35.7) 44 (30.6)
Multiple 13 (14.8) 10 (17.9) 23 (16.0)
Concomitant HIV and AIDS diagnosisd
Yes 55 (64.0) 28 (50.0) 83 (58.5) 0.118
No 31 (36.0) 28 (50.0) 59 (41.5)
CD4+ cell count (106/L)e
<100 28 (36.4) 40 (72.7) 68 (51.5) <0.001
100 49 (63.6) 15 (27,3) 64 (48.5)
Pneumocystis jiroveci pneumonia prophylaxis
Yes 43 (48.9) 54 (96.4) 97 (67.4) <0.001
Never used 45 (51.1) 2 (3.6) 47 (32.6)
Initial treatmentf
No treatment 47 (64.4) 21 (40.4) 68 (54.4) <0.001g
Monotherapy 17 (23.3) 2 (3.8) 19 (15.2)
Double ART 7 (9.6) 8 (15.4) 15 (12.0)
HAART 2 (2.7) 21 (40.4) 23 (18.4)
Antiretroviral treatment (ever)h
No treatment 39 (44.3) 5 (8.9) 44 (30,6) <0.001g
Monotherapy 34 (38.6) 4 (7.1) 38 (26.4)
Dual ART 21 (23.9) 8 (14.3) 29 (20.1)
HAART 17 (19.3) 48 (85.7) 65 (45.1)
a Comparison of heterosexual vs MSM/bisexual
b Total >144 because some patients had multiple presenting illnesses
c Comparison of cases of tuberculosis
d N=142 because the date of diagnosis of HIV infection was not known for 2 patients
e N=132 because of missing data
f Type of treatment given within three months after AIDS diagnosis. N=125 because patients who died within one month of AIDS
and those receiving treatment before AIDS diagnosis were excluded.
g Comparison of HAART
h Total >144 because patients moved from categories
HAART – highly active antiretroviral treatment, ART – antiretroviral treatment, MSM – men who have sex with men
apy excluded, the survival after 6 months was markedly
improved for patients in the early HAART era (Hazard
Ratio, (HR) = 0.11, 95% confidence interval (CI) =
0.04–0.29, p<0.0001) compared to the pre-HAART era.
Survival at 6 months was similar in the pre-HAART and
HAART era (HR=0.68, 95% CI=0.3–1.52, p=0.34) in
this model and other predictors did not change signifi-
cantly compared to the model that included antiretro-
viral treatment.
The initial HAART regimen used was a non-boosted
indinavir combination in 38 (58.5%) patients, a low-dose
ritonavir boosted indinavir combination in 13 (20.0%)
patients, and 10 (15.4%) patients started with a non-
nucleoside analogue plus indinavir combination. Two pa-
tients started with a full dose ritonavir regimen and one
with a nelfinavir, and efavirenz based combination.
Discussion
Survival after the first AIDS event has markedly im-
proved after introduction of HAART in Croatia. However,
during the first six months after AIDS diagnosis, sur-
vival was similar for the pre-HAART era (1986–1996)
and early HAART era (1997–2000). In addition, the one–
year probability of death after AIDS was still high in the
early HAART era (27.2%), suggesting that improvements
in the treatment of opportunistic infections are still need-
ed. Since our patients started HAART relatively late after
AIDS diagnosis, earlier administration of HAART might
have improved survival. Those who died in the early
HAART era presented most frequently with multiple op-
portunistic infections (22.2%) and progressive multifocal
leukoencephalopathy (16.7%). The effect of CD4+ cell
count at the time of AIDS diagnosis, on survival is antici-
pated to be less pronounced over time; however, it was
still significantly associated with survival at 2 years after
AIDS diagnosis in our patient population. Similarly to
patients from the pre HAART era12 the type of AIDS
-presenting illness was a significant predictor of survival.
Studies conducted prior to the introduction of HAART
from both industrialized and de- veloping countries have
shown an association between specific opportunistic dis-
eases and survival13,15–18. Patients with lymphoma and
progressive multifocal leukoencephalopathy had shorter
survival, conversely to those having extrapulmonary tu-
berculosis and Kaposi’s sarcoma13,14,16,17.
The improvement in survival observed in our study is
similar to that reported from many developed countries
since 1995. At 36 months, 67% of United States9 and 58%
of AIDS patients from Brazil10 diagnosed in 1996 were
alive, compared to 68.4% of our patients diagnosed in the
period 1997–2000. The probability of three-year survival
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TABLE 2
PREDICTORS OF SURVIVAL ON BIVARIATE AND MULTIVARIATE COX PROPORTIONAL HAZARD ANALYSIS
Predictorsa
Bivariate (N=144)b Multivariate (N=120)c
Hazard
ratio
95% CI p
Hazard
ratio
95% CI p
Gender (male versus female) 1.48 0.80–2.73 0.20
Age (< 40 versus  40) 0.81 0.54–1.23 0.33
Exposure category (MSM/bisexual versus other) 1.14 0.75–1.72 0.54
Concomitant HIV and AIDS diagnosis (yes versus no) 1.01 0.67–1.54 0.96
Antiretroviral therapy
Monotherapy 1.36 0.81–2.26 0.24 2.01 1.04–3.92 0.04
Double therapy 0.50 0.27–0.95 0.03 0.72 0.36–1.42 0.34
HAART 0.19 0.10–0.38 <0.001 0.31 0.13–0.72 0.006
Year of diagnosis (1997–2000 versus 1986–1996)
Survival times: 0–5 months 0.59 0.29–1.19 0.14
 6 months 0.15 0.07–0.32 <0.001
CD4+ cell counts (<100  106/L versus  100  106/L)
Survival times: 0–23 months 1.20 0.73–2.04 0.45 1.96 1.12–3.43 0.02
 24 months 0.43 0.15–1.20 0.11 0.70 0.22–2.27 0.56
Presenting diagnosis (tuberculosis/fungald versus other) 0.46 0.29–0.73 0.001 0.53 0.32–0.90 0.01
Multiple initial presenting illnesses (yes versus no) 0.96 0.52–1.76 0.89
PCP prophylaxis (yes versus no) 0.39 0.24–0.63 0.001 0.50 0.25–1.00 0.05
a The reference category is the second one in parenthesis.
b Some categories have <144 patients because there were missing data on the CD4+ cell count and because patients who started
antiretroviral treatment or P. jiroveci prophylaxis before AIDS were excluded.
c Patients who started antiretroviral treatment or P. jiroveci prophylaxis before AIDS were excluded as were those with missing data
on CD4+ cell counts.
d Oesophageal candidiasis and cryptococcal meningitis.
MSM – men who have sex with men, HAART – highly active antiretroviral treatment, CI – confidence interval
from the time when CD4+ lymphocyte count falls to
<200  106/L in different European countries ranged
from 78–88%19. We were also able to evaluate the effect of
specific antiretroviral treatment regiments comparing
the use of monotherapy, double combination, and triple
combination therapies. The relative hazard found in our
study (HR=0.31) was similar to that from larger studies
from the United States (HR=0.36)9 and Italy (HR=0.36)8.
Our study findings are limited by the small number of
patients studied; some predictors like PCP prophylaxis,
age or gender might have been significant in a larger
sample. To assess the effect of AIDS-defining illnesses we
had to combine many different opportunistic diseases
and we were able to stratify our patients into only two
CD4+ cell strata. Since the period of study was relatively
large, improvements in the treatment of opportunistic
disease might have occurred and influenced survival.
Despite the limitations of our sample size, we studied
a well-defined population at one center and obtained
findings similar to larger cohorts. As expected, combina-
tion therapy with a protease inhibitor markedly im-
proved survival in AIDS patients in Croatia. However,
the occurrence of opportunistic diseases can be largely
prevented by earlier diagnosis and treatment of HIV in-
fection, and prophylaxis against opportunistic infections.
Unfortunately, there are still patients who are diagnosed
with HIV infection at an advanced stage of HIV disease.
Currently, in Croatia around 30% of all newly diagnosed
HIV-positive patients present with an AIDS- defining
event. Better public information, patient education, wider
screening of high-risk populations, and improved out-
reach to risk groups could lead to earlier HIV diagnosis
and thus significantly avoiding the morbidity and mor-
tality associated with AIDS- defining diseases.
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IZRAZITO POBOLJ[ANJE PRE@IVLJAVANJA U ODRASLIH BOLESNIKA IZ HRVATSKE
OBOLJELIH OD AIDS-A NAKON UVO\ENJA VRLO DJELOTVORNOG ANTIRETROVIRUSNOG
LIJE^ENJA
S A @ E T A K
Usporedili smo pre`ivljavanje bolesnika nakon dijagnoze AIDS-a u Hrvatskoj u razdoblju 1986–1996. g. s razdob-
ljem 1997– 2000. g. 72 (81,8%) od 88 bolesnika iz 1986–1996. g. i 18 (32,1%) od 56 iz 1997–2000. g. je umrlo. Pre-
`ivljavanje nakon prve AIDS-definiraju}e bolesti se zna~ajno pobolj{alo u razdoblju 1997–2000 u odnosu na razdoblje 1986–
1996 (prilago|eni omjer hazarda (HR) za bolesnike koji su pre`ivjeli vi{e od 6 mjeseci: 0,11, 95% CI: 0,04–0,29). Broj
CD4+ limfocita < 100  106/L je tako|er bio neovisni ~imbenik pre`ivljavanja za bolesnike koji su pre`ivjeli 2 godine
(prilago|eni HR=1,96, 95%CI=1,1–3,43, p=0,02). Bolesnici s tuberkulozom ili gljivi~nom infekcijom imali su bolje pre`iv-
ljavanje u usporedbi s drugim dijagnozama (prilago|eni HR=0,53, 95%CI=0,32–0,90, p=0,01). Me|utim, usprkos izrazito
boljem pre`ivljavanju zbog kombinirane antiretrovirusne terapije, smrtnost 6 mjeseci od AIDS-a je bila sli~na u oba raz-
doblja, a smrtnost nakon jedne godine od AIDS-a je bila jo{ uvijek zna~ajna (27,2%) u razdoblju 1997–2000.
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